Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 16/20 | 1.00 |
| ▸ | METAP1 | P53582 | 10/20 | 1.00 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7350481 | 0.99 | METAP2 (0.98) | METAP2METAP1NLNCHRNB2CHRNB4 | |
| SCHEMBL14984958 | 0.87 | METAP2 (0.76) | METAP2METAP1NLNCHRNB2CHRNB4 | |
| SCHEMBL12022088 | 0.85 | METAP2 (0.74) | METAP2METAP1NLNCHRNB2CHRNB4 | |
| SCHEMBL21017020 | 0.85 | METAP2 (0.74) | METAP2METAP1NLNCHRNB2CHRNB4 | |
| SCHEMBL7357828 | 0.80 | METAP2 (0.67) | METAP2METAP1ACP3 | |
| Hydrochloric Acid SCHEMBL7353287 | 0.79 | METAP2 (0.66) | METAP2METAP1ACP3 | |
| SCHEMBL7356908 | 0.78 | METAP2 (0.70) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL7355712 | 0.77 | METAP2 (0.69) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26027575 | 0.73 | METAP2 (0.62) | METAP2METAP1NLN | |
| SCHEMBL7360432 | 0.73 | METAP2 (0.57) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | claimed |
| EP-3858385-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | Syndevrx, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20110294952-A1 | Optimized Drug Conjugates | SynDevRX (US) | 2011-12-01 | — | — | US | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294952-A1 | Optimized Drug Conjugates | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885METAP1 1935/4885NLN 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.